NVO•benzinga•
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target
Summary
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga